12:00 AM
 | 
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MP0112: Phase I/II data

An open-label, dose-escalation Phase I/II trial in 18 evaluable patients with DME showed that a single intravitreal injection of MP0112 improved median BCVA from baseline to week 12 by 4 letters at the 0.04 mg dose, by...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >